Another study uncovered the therapeutic potential of GSK‐3β pathway inhibition to restore neurodevelopmental defects in hereditary spastic paraplegia (HSP) patients with SPG11 mutations (Mishra et al, 2016). This evidence concerns the gene GSK3B and hereditary spastic paraplegia.